On May 16, 2014, OXiGENE, Inc. (NASDAQ:OXGN) announced that, effective May 15, 2014, Peter J. Langecker, M.D., Ph.D., has resigned from his positions as the Company’s Chief Executive Officer and a member of the Board of Directors and that David (Dai) Chaplin, Ph.D., a current member of the Board of Directors, has been appointed as the Company’s President and Chief Executive Officer. OXiGENE Inc. (NASDAQ:OXGN) stock opened today at $2.93 and is currently trading at $3.02. The stock showed a negative weekly performance of -0.68%.
Merrimack Pharmaceuticals (NASDAQ:MACK) Director Gary Crocker bought 9,400 shares of Merrimack Pharmaceuticals stock on the open market in a transaction dated Monday, May 19th. The stock was purchased at an average cost of $6.68 per share, for a total transaction of $62,792.00. Following the purchase, the director now directly owns 2,804,571 shares of the company’s stock, valued at approximately $18,734,534. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) stock opened at $6.83, in current trading session and currently is at $7.16, by gaining 4.37%. The 52 week range of $2.05 – $7.65. Company’s market capitalization is 740.38 million.
Aegis reiterated their hold rating on shares of Inovio Pharmaceuticals (NYSE:INO) in a research report sent to investors on Wednesday morning. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) stock is currently trading at $2.19. The EPS of the stock is -0.34. Company’s market capitalization is 526.98 million.
Geron Corporation (NASDAQ:GERN) is facing a class-action lawsuit that accuses it of making false or misleading statements regarding its drug. Geron Corporation (NASDAQ:GERN) stock opened the session at $1.98, and now is at $2.04. The 52 week range of the Geron Corporation (NASDAQ:GERN) stock remained $1.05 – $7.79 and the day range was $1.96 – $2.08.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) CEO Patrick Mcenany bought 25,000 shares of Catalyst Pharmaceutical Partners stock on the open market in a transaction dated Wednesday, May 21st. The shares were purchased at an average cost of $1.89 per share, with a total value of $47,250.00. Following the completion of the transaction, the chief executive officer now directly owns 3,656,247 shares in the company, valued at approximately $6,910,307. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) stock opened today at $1.93 and is currently trading at $2.04. The stock showed a positive weekly performance of 4.52%.